or Try an Advanced Search...

    Holdings

    Symbol Grade Price % Change Allocation
    NVO D -0.78 1.94

    Represented by ETF Holdings

    Keywords: Anti Diabetic Drugs Biopharmaceutical Diabetes Diabetes Care Endocrine System Glucagon Like Peptide 1 Growth Hormone Growth Hormone Therapy Haemophilia Hormone Therapy Hormones Inflammation Insulin Life Sciences Obesity Peptide Hormones Pharmaceutical Products Pharmaceuticals Segment Related Delivery Systems
    Industries: Biotechnology

    Recent News for John Hancock International High Dividend ETF & its Holdings

    Date Stock Title
    May 3 NVO Amgen's peek at its GLP-1 drug trial results heightens competition in obesity market
    May 3 NVO Novo Nordisk A/S (NYSE:NVO) Q1 2024 Earnings Call Transcript
    May 3 NVO Analyst unveils Amgen stock price target after weight-loss drug data
    May 3 NVO The FTC Cracks Down On Novo Nordisk's Ozempic
    May 3 NVO Weight-loss drug competition heats up. Is Wegovy in trouble?
    May 3 NVO Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims
    May 3 NVO Amgen Knocks Novo Nordisk's Ozempic Stock Rally. Its Stock Is Flying.
    May 3 NVO FTC Seeks More Information on $16.5 Billion Novo-Catalent Deal
    May 3 NVO Catalent, Novo Nordisk receive FTC request for more information
    May 3 NVO US FTC seeks more information on Novo Nordisk parent-Catalent deal
    May 3 NVO UPDATE 2-US FTC seeks more information on Novo Nordisk parent-Catalent deal
    May 3 NVO Job Market Cools In April: Payrolls Miss Forecasts, Wages Rise Less Than Expected
    May 3 NVO How the CFOs of Eli Lilly and Novo Nordisk are coping with ‘unprecedented demand’ for weight-loss drugs
    May 3 NVO This Is a Huge Sigh of Relief for Novo Nordisk Investors
    May 3 NVO Novo Nordisk drops 5% after rival Amgen teases weight-loss drug data
    May 3 NVO Novo slides as Amgen fuels obesity drug competition fears
    May 3 NVO Here’s How Novo Holdings’ Catalent (CTLT) Acquisition Affects Laughing Water Capital
    May 2 NVO Weight Loss Competition Heats Up In Britain, Online Pharmacies Slash Prices for Wegovy and Mounjaro
    May 2 NVO Novo Nordisk slides while Moderna pops: Tale of two pharma stocks
    May 2 NVO Market Chatter: Novo Nordisk, Eli Lilly's Weight-Loss Drugs Get Price Cuts in UK
    John Hancock Exchange-Traded Fund Trust - John Hancock International High Dividend ETF is an exchange traded fund launched and managed by John Hancock Investment Management LLC. The fund is co-managed by Manulife Investment Management (US) LLC. It invests in public equity markets of global ex-US region. The fund invests in stocks of companies operating across diversified sectors. The fund invests in growth and value stocks of companies across diversified market capitalization. The fund employs proprietary research to create its portfolio. Traded Fund Trust - John Hancock International High Dividend ETF was formed in December 20, 2022 and is domiciled in United States.
    Exchange Traded Funds SPDR
    Back to the Main JHID Page...